TR201914043A1 - EFERVESAN TABLET FORMULATIONS CONTAINING DAPAGLYFLOZIN AND METFORMIN - Google Patents
EFERVESAN TABLET FORMULATIONS CONTAINING DAPAGLYFLOZIN AND METFORMINInfo
- Publication number
- TR201914043A1 TR201914043A1 TR2019/14043A TR201914043A TR201914043A1 TR 201914043 A1 TR201914043 A1 TR 201914043A1 TR 2019/14043 A TR2019/14043 A TR 2019/14043A TR 201914043 A TR201914043 A TR 201914043A TR 201914043 A1 TR201914043 A1 TR 201914043A1
- Authority
- TR
- Turkey
- Prior art keywords
- metformin
- efervesan
- dapaglyflozin
- tablet formulations
- formulations containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Buluş, dapagliflozin veya dapagliflozinin farmasötik olarak kabul edilebilir bir tuzu ve metformin veya metforminin farmasötik olarak kabul edilebilir bir tuzu ile gerçekleştirilen efervesan tablet formülasyonlar ile ilgilidir.The invention relates to effervescent tablet formulations made with dapagliflozin or a pharmaceutically acceptable salt of dapagliflozin and metformin or a pharmaceutically acceptable salt of metformin.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2019/14043A TR201914043A1 (en) | 2019-09-16 | 2019-09-16 | EFERVESAN TABLET FORMULATIONS CONTAINING DAPAGLYFLOZIN AND METFORMIN |
| EP20866500.0A EP4031122A4 (en) | 2019-09-16 | 2020-08-05 | EFFERVESCENT TABLET FORMULATIONS INCLUDING DAPAGLIFLOZIN AND METFORMIN |
| PCT/TR2020/050687 WO2021054912A1 (en) | 2019-09-16 | 2020-08-05 | Effervescent tablet formulations comprising dapagliflozin and metformin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2019/14043A TR201914043A1 (en) | 2019-09-16 | 2019-09-16 | EFERVESAN TABLET FORMULATIONS CONTAINING DAPAGLYFLOZIN AND METFORMIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201914043A1 true TR201914043A1 (en) | 2021-04-21 |
Family
ID=74883168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/14043A TR201914043A1 (en) | 2019-09-16 | 2019-09-16 | EFERVESAN TABLET FORMULATIONS CONTAINING DAPAGLYFLOZIN AND METFORMIN |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4031122A4 (en) |
| TR (1) | TR201914043A1 (en) |
| WO (1) | WO2021054912A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2599950A (en) * | 2020-10-16 | 2022-04-20 | Zentiva Ks | Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same |
| EP4079296A1 (en) * | 2021-04-21 | 2022-10-26 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A bilayer tablet formulation comprising amorphous dapagliflozin and metformin |
| CN118078745B (en) * | 2024-04-07 | 2025-01-24 | 安徽新世纪药业有限公司 | Preparation method of metformin hydrochloride oral solution |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007038979A1 (en) * | 2005-09-22 | 2007-04-12 | Swissco Development Ag | Effervescent metformin composition and tablets and granules made therefrom |
| ES2689107T3 (en) | 2009-11-13 | 2018-11-08 | Astrazeneca Ab | Bilayer tablet formulations |
| EP2809311A1 (en) * | 2012-01-31 | 2014-12-10 | Mahmut Bilgic | Effervescent tablet formulations comprising the combination of voglibose and metformin |
| WO2017098481A1 (en) * | 2015-12-12 | 2017-06-15 | Steerlife India Private Limited | Effervescent compositions of metformin and processes for preparation thereof |
| WO2018185669A1 (en) | 2017-04-07 | 2018-10-11 | Zenvision Pharma Llp | Effervescent compositions comprising saxagliptin or salt thereof |
-
2019
- 2019-09-16 TR TR2019/14043A patent/TR201914043A1/en unknown
-
2020
- 2020-08-05 WO PCT/TR2020/050687 patent/WO2021054912A1/en not_active Ceased
- 2020-08-05 EP EP20866500.0A patent/EP4031122A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021054912A1 (en) | 2021-03-25 |
| EP4031122A1 (en) | 2022-07-27 |
| EP4031122A4 (en) | 2023-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220008A1 (en) | Parp1 inhibitors | |
| TR201916829A2 (en) | DUAL-LAYER TABLET FORMULATIONS CONTAINING DAPAGLYFLOZIN AND METFORMIN | |
| DOP2020000102A (en) | HELPFUL COMPOUNDS TO INHIBIT CDK7 | |
| PH12022551226A1 (en) | Pyrrolotriazine compounds acting as mnk inhibitor | |
| PH12019550249A1 (en) | Solid compositions for oral administration | |
| TN2017000495A1 (en) | Notch pathway signaling inhibitor compounds. | |
| TR201914043A1 (en) | EFERVESAN TABLET FORMULATIONS CONTAINING DAPAGLYFLOZIN AND METFORMIN | |
| EA202090542A1 (en) | HIGHLY CONCENTRATED MEDICINAL FORMS OF Pridopidine | |
| CL2020002199A1 (en) | Methylactam ring compound and pharmaceutical use thereof. | |
| MX2020005483A (en) | Ildr2 antagonists and combinations thereof. | |
| PH12020551985A1 (en) | Anti-human tlr7 antibody | |
| GEP20237486B (en) | Formulations of copanlisib | |
| MX394833B (en) | FORMULATIONS WITH IMPROVED STABILITY. | |
| TR201721700A2 (en) | DISTRIBUTED FORMULATIONS OF SAXAGLIPT IN THE MOUTH | |
| TR201722367A2 (en) | PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL APPLICATION CONTAINING LACOSAMIDE | |
| TR201713954A2 (en) | PHARMACEUTICAL COMBINATIONS OF TENOFOVIR, EMTRISITABIN AND EAVIRENZINE | |
| TR201913472A2 (en) | A combination comprising vildagliptin and metformin | |
| EA201890929A1 (en) | LOW DOSES OF DIPYRIDAMOL COMPOSITIONS FOR ORAL ADMINISTRATION AND THEIR USE | |
| TR201914406A2 (en) | SOLID ORAL PHARMACEUTICAL FORMULATIONS CONTAINING SAPROPTERIN DIHYDROCHLORIDE AND AT LEAST ONE PHARMACEUTICAL EXCIPIENT | |
| TR201914416A1 (en) | Effervescent formulations of sapropterin dihydrochloride | |
| TR201914420A2 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING SAPROPTERIN DIHYDROCHLORIDE AND AT LEAST ONE ANTIOXIDANT | |
| TR201619184A2 (en) | DONEPESIL AND MEMANTINE CONTAINING CAPSULES | |
| BR112022012584A2 (en) | SUBSTITUTED HYDROXYSTIBENE COMPOUNDS AND DERIVATIVES, SYNTHESIS AND USE OF THEM | |
| JOP20200005A1 (en) | Pharmacy fixtures | |
| TR2023018919A2 (en) | PHARMACEUTICAL EXTENDED-RELEASE FORMULATIONS CONTAINING LINAGLIPTINE AND METFORMIN |